MCKESSON WKN: 893953 ISIN: US58155Q1031 Kürzel: MCK Forum: Aktien Thema: Hauptdiskussion

Weiß jemand ob die NettoMarge tatsächlich nur bei 1-2% liegt. Ich konnte nichts genaueres finden. Für ein „Medizinvertriebs“ Unternehmen aus meiner Sicht nicht nachvollziehbar mit der geringen Rendite? 🤔

https://www.stocktitan.net/news/MCK/mc-kesson-corporation-announces-sale-of-rexall-and-well-ca-kw1611u1aid4.html

Habe den heutigen Dip genutzt.

https://www.businesswire.com/news/home/20240807481181/en/McKesson-Corporation-Reports-Fiscal-2025-First-Quarter-Results

McKesson Raises Quarterly Dividend by 15% to $0.71 Per Share https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/mckesson-raises-quarterly-dividend/

McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance https://www.businesswire.com/news/home/20240207770220/en/

https://www.businesswire.com/news/home/20231031995376/en/ McKesson Corporation Reports Fiscal 2024 Second Quarter Results and Raises Full Year Guidance

https://www.businesswire.com/news/home/20230801510861/en/

- Adj EPS: $7.27 (est  $5.86) - Revenue: $74.5B (est  $70.12B)

https://www.benzinga.com/pressreleases/23/07/b33342907/mckesson-raises-quarterly-dividend-by-15-to-0-62-per-share McKesson Raises Quarterly Dividend by 15% to $0.62 Per Share

McKesson Corporation Reports Fiscal Fourth-Quarter and Full-year Results and Raises Long-Term Segment Growth Targets https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2023/McKesson-Reports-Fiscal-2023-Fourth-Quarter-Full-Year-Results/

https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2023/McKesson-Medical-Surgical-Government-Solutions-Awarded-Federal-Supply-Schedule-Contract/

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M https://seekingalpha.com/news/3930812-mckesson-non-gaap-eps-of-6_90-beats-0_54-revenue-of-70_5b-misses-480m • McKesson press release (NYSE:MCK): Q3 Non-GAAP EPS of $6.90 beats by $0.54. • Revenue of $70.5B (+2.8% Y/Y) misses by $480M. • ... • Increased fiscal 2023 Adjusted Earnings per Diluted Share guidance range to $25.75 to $26.15, from the previous range of $24.45 to $24.95 vs. $24.80 consensus

https://www.businesswire.com/news/home/20230131006173/en/McKesson-Corporation-Reports-Fiscal-2023-Third-Quarter-Results

McKesson (NYSE:MCK) Price Target Increased to $420.00 by Analysts at Morgan Stanley https://www.marketbeat.com/instant-alerts/nyse-mck-a-buy-or-sell-right-now-2023-01/

Produzieren die auch Medikamente oder vertreiben sie sie nur?